CAR T cells target senescent cells, improve healthspan in mice

CAR T cell therapy pioneered at Memorial Sloan Kettering Cancer Center (MSK) is showing promise in treating age-related diseases, such as metabolic decline, and could extend lifespan. The approach, using engineered immune cells to target senescent (nondividing) cells, has potential for diseases like chronic obstructive pulmonary disease (COPD), nonalcoholic steatohepatitis (NASH), osteoarthritis, metabolic syndrome, and neurodegenerative diseases, according to lab research. The experimental CAR T cells improved metabolic health in older and high-fat diet-fed mice without major side effects, signaling a potential lasting benefit of a single treatment. Researchers believe treatments can be less toxic and extend diseases targeted in the coming years.

Source link

error: Content is protected !!